Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.

Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS.

Clin Cancer Res. 2019 Oct 1;25(19):5818-5831. doi: 10.1158/1078-0432.CCR-18-4022. Epub 2019 Jul 4.

PMID:
31273010
2.

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.

Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, Butler R, Shafren D, Au G, Knowles M, Harrington K, Vile R, Melcher A, Pandha H.

Mol Ther Oncolytics. 2018 Feb 14;9:1-12. doi: 10.1016/j.omto.2018.02.001. eCollection 2018 Jun 29.

3.

Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H.

Clin Exp Immunol. 2014 Aug;177(2):428-38. doi: 10.1111/cei.12332.

4.

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G.

Cancer Immunol Immunother. 2014 Feb;63(2):175-83. doi: 10.1007/s00262-013-1502-y. Epub 2013 Nov 29.

PMID:
24292263
5.

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS.

Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12.

6.

Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?

Middleton GW, Annels NE, Pandha HS.

Cancer Immunol Immunother. 2012 Jan;61(1):1-7. doi: 10.1007/s00262-011-1151-y. Epub 2011 Nov 16. Review.

PMID:
22086162
7.

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW.

Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. doi: 10.1007/s00262-011-1028-0. Epub 2011 Jun 5.

8.

The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis.

Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS.

Mol Ther. 2010 Dec;18(12):2085-93. doi: 10.1038/mt.2010.189. Epub 2010 Sep 14.

9.

Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7.

Faaij CM, Willemze AJ, Révész T, Balzarolo M, Tensen CP, Hoogeboom M, Vermeer MH, van Wering E, Zwaan CM, Kaspers GJ, Story C, van Halteren AG, Vossen JM, Egeler RM, van Tol MJ, Annels NE.

Pediatr Blood Cancer. 2010 Aug;55(2):344-8. doi: 10.1002/pbc.22500.

PMID:
20582977
10.

Decrease of skin infiltrating and circulating CCR10+ T cells coincides with clinical improvement after topical tacrolimus in Omenn syndrome.

Faaij CM, Annels NE, Ruigrok G, van der Burg M, Ball LM, Bredius RG, van Tol MJ, Lankester AC.

J Invest Dermatol. 2010 Jan;130(1):308-11. doi: 10.1038/jid.2009.196. No abstract available.

11.

No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies.

da Costa CE, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, Björgvinsdóttir H, Debiec-Rychter M, de Krijger RR, Hogendoorn PC, Egeler RM, Annels NE.

Genes Chromosomes Cancer. 2009 Mar;48(3):239-49. doi: 10.1002/gcc.20634.

PMID:
19051326
12.

Differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease.

da Costa CE, Egeler RM, Hoogeboom M, Szuhai K, Forsyth RG, Niesters M, de Krijger RR, Tazi A, Hogendoorn PC, Annels NE.

J Pathol. 2007 Jun;212(2):188-97.

PMID:
17447723
13.

Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.

Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, van Baarle D, Egeler RM, van Tol MJ, Lankester AC.

Clin Infect Dis. 2006 Jun 15;42(12):1743-8. Epub 2006 May 4.

PMID:
16705581
14.

A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease.

Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, Révész T, Egeler RM, van Tol MJ, Annels NE.

Br J Haematol. 2006 Jun;133(5):538-49.

PMID:
16681643
15.

Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis.

da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM.

J Exp Med. 2005 Mar 7;201(5):687-93.

16.

Langerhans cell histiocytosis: a pathologic combination of oncogenesis and immune dysregulation.

Egeler RM, Annels NE, Hogendoorn PC.

Pediatr Blood Cancer. 2004 May;42(5):401-3. No abstract available.

PMID:
15049009
17.

Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL.

Annels NE, Willemze AJ, van der Velden VH, Faaij CM, van Wering E, Sie-Go DM, Egeler RM, van Tol MJ, Révész T.

Blood. 2004 Apr 1;103(7):2806-8. Epub 2003 Dec 4.

PMID:
14656893
18.

Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis.

Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM.

J Exp Med. 2003 May 19;197(10):1385-90. Epub 2003 May 12.

19.

Langerhans-cell histiocytosis 'insight into DC biology'.

Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM.

Trends Immunol. 2003 Apr;24(4):190-6.

PMID:
12697451
20.

Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential.

Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ, Soares MV, Hislop AD, Annels NE, Rickinson AB, Salmon M, Akbar AN.

Blood. 2002 Aug 1;100(3):933-40.

PMID:
12130505
21.

Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB.

J Exp Med. 2002 Apr 1;195(7):893-905.

22.

Memory T cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic and migratory characteristics.

Faint JM, Annels NE, Curnow SJ, Shields P, Pilling D, Hislop AD, Wu L, Akbar AN, Buckley CD, Moss PA, Adams DH, Rickinson AB, Salmon M.

J Immunol. 2001 Jul 1;167(1):212-20.

23.

Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response.

Annels NE, Callan MF, Tan L, Rickinson AB.

J Immunol. 2000 Nov 1;165(9):4831-41.

24.

T-cell memory: lessons from Epstein-Barr virus infection in man.

Rickinson AB, Callan MF, Annels NE.

Philos Trans R Soc Lond B Biol Sci. 2000 Mar 29;355(1395):391-400. Review.

25.

A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.

Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MF.

J Immunol. 1999 Feb 1;162(3):1827-35.

26.

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.

Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB.

J Exp Med. 1997 May 5;185(9):1605-17.

27.

Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.

Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB.

J Exp Med. 1996 Nov 1;184(5):1801-13.

Supplemental Content

Loading ...
Support Center